| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/17/2004 | US20040115202 monospecific antibody which specifically binds an epitope of a mammalian DPPIV (dipeptidyl peptidase IV, also known as CD26). |
| 06/17/2004 | US20040115181 Composition for transmucosal adminstration containing conenzyme q as the active ingredient |
| 06/17/2004 | US20040115129 Nucleic acid sequence 1 or 3; amino acid sequence 2 or 4 |
| 06/17/2004 | DE20220901U1 Film coating composition for controlled release of active ingredient e.g. metoprolol, comprises an acrylic polymer dispersion, a surfactant, sodium stearyl fumarate and a water-containing liquid |
| 06/17/2004 | CA2508319A1 Jnk inhibitors |
| 06/17/2004 | CA2508309A1 Remedy |
| 06/17/2004 | CA2507780A1 Indol derivatives and their use as kinase inhibitors |
| 06/17/2004 | CA2507763A1 Fused 1,3-dihydro-imidazole ring compounds |
| 06/17/2004 | CA2507742A1 Novel azole derivatives |
| 06/17/2004 | CA2507665A1 Preventive or remedy for diseases caused by hyperglycemia |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/17/2004 | CA2481489A1 Cysteine protease inhibitor |
| 06/16/2004 | EP1428877A1 Novel protein and dna thereof |
| 06/16/2004 | EP1428826A2 Crystal forms of cytostatics |
| 06/16/2004 | EP1428822A2 1-phenylpiperazine derivative as modulators of dopamine neurotransmission |
| 06/16/2004 | EP1428820A1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications |
| 06/16/2004 | EP1428540A1 Tissue regenerative composition |
| 06/16/2004 | EP1428537A1 Stabilized preparations containing antibody |
| 06/16/2004 | EP1428533A2 Use of thiazolidine- or pyrrolidine-derivatives of aminoacids as antihyperglycemic agents |
| 06/16/2004 | EP1428531A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| 06/16/2004 | EP1428529A1 Apolipo protein e secretion promoters |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427855A2 Method and reagents for identifying gene targets for treating breast cancer |
| 06/16/2004 | EP1427844A1 New assay for inhibitors of translocases |
| 06/16/2004 | EP1427842A2 Mid 9002, a human sulfatase family member and uses therefor |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427838A1 Plant enzymes for bioconversion |
| 06/16/2004 | EP1427831A1 Yeast membrane protein expression system and its application in drug screening |
| 06/16/2004 | EP1427830A2 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
| 06/16/2004 | EP1427825A2 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 06/16/2004 | EP1427820A2 Modified factor ix |
| 06/16/2004 | EP1427813A2 Method for dendritic cells-based immunotherapy of tumors using combination therapy |
| 06/16/2004 | EP1427753A2 Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing them and their applications |
| 06/16/2004 | EP1427732A1 Spirocyclic-6,7-dihydro-5h-pyrazolo 1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 06/16/2004 | EP1427729A1 Carbazole derivatives and their use as npy5 receptor antagonists |
| 06/16/2004 | EP1427728A1 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES |
| 06/16/2004 | EP1427727A1 Compounds which inhibit the release of inflammatory cytokines |
| 06/16/2004 | EP1427723A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 06/16/2004 | EP1427720A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427717A1 Bioprecursors for percutaneous application |
| 06/16/2004 | EP1427712A2 Dye-azide compounds for dual phototherapy |
| 06/16/2004 | EP1427711A1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents |
| 06/16/2004 | EP1427709A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/16/2004 | EP1427706A1 Substituted pyrazolo compounds for the treatment of inflammation |
| 06/16/2004 | EP1427696A1 Ccr-3 receptor antagonists v |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427424A2 Lpa receptor agonists and antagonists and methods of use |
| 06/16/2004 | EP1427423A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| 06/16/2004 | EP1427422A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
| 06/16/2004 | EP1427421A1 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents |
| 06/16/2004 | EP1427414A1 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines |
| 06/16/2004 | EP1427411A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo 3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 06/16/2004 | EP1427409A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427403A2 Valproic acid and derivatives for the combination treatment of human cancers, tumor metastasis and minimal residual disease |
| 06/16/2004 | EP1427401A2 Method for reducing hypertension and heart failure |
| 06/16/2004 | EP1427349A2 Interleukin-12 as a veterinary vaccine adjuvant |
| 06/16/2004 | EP1427326A2 Combination therapy for the treatment of cancer |
| 06/16/2004 | EP1427289A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption |
| 06/16/2004 | EP1355646A4 Muscarinic receptor agonists |
| 06/16/2004 | EP1351958B1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 06/16/2004 | EP1339406B1 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
| 06/16/2004 | EP1278771A4 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
| 06/16/2004 | EP1268469B1 N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants |
| 06/16/2004 | EP1263751B1 2-phenylpyran-4-one derivatives |
| 06/16/2004 | EP1257556B1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |
| 06/16/2004 | EP1246839B1 Depsipeptide and congeners thereof for use as immunosuppressants |
| 06/16/2004 | EP1244643B1 Tryptase inhibitors |
| 06/16/2004 | EP1221950B1 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 06/16/2004 | EP1194411B1 Benzoylpyridazines |
| 06/16/2004 | EP1144425B1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 06/16/2004 | EP1119570B1 Tricyclic delta3-piperidines as pharmaceuticals |
| 06/16/2004 | EP1109810B1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
| 06/16/2004 | EP1089963B1 Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release |
| 06/16/2004 | EP1071658B1 Btk inhibitors and methods for their identification and use |
| 06/16/2004 | EP1030670B1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents |
| 06/16/2004 | EP0983243B1 Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
| 06/16/2004 | EP0906102B1 A process for regulating vagal tone |
| 06/16/2004 | EP0881908B1 Use of fibroblast growth factors to stimulate bone growth |
| 06/16/2004 | EP0807105B1 Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
| 06/16/2004 | EP0788308B1 Polymeric wound healing accelerators |
| 06/16/2004 | CN1505640A T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection |
| 06/16/2004 | CN1505638A Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| 06/16/2004 | CN1505631A Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands |
| 06/16/2004 | CN1505630A Pyrazolo[1,5-a]pyridines and medicaments containing thereof |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505625A Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 06/16/2004 | CN1505623A Benzoaxathiepin derivatives and their use as medicines |
| 06/16/2004 | CN1505618A Dimeric isoflavones |
| 06/16/2004 | CN1505613A Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents |
| 06/16/2004 | CN1505607A Peptide-deformylase inhibitors |
| 06/16/2004 | CN1505603A Substituted benzoic ac id derivatives exhibiting nf-ª—b inhibiting activity |
| 06/16/2004 | CN1505527A Combination therapy using anti-angiogenic agents and tnfa |
| 06/16/2004 | CN1505521A Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof |
| 06/16/2004 | CN1505514A Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| 06/16/2004 | CN1505513A Aqueous cilostazol preparation for injection |
| 06/16/2004 | CN1505511A Use of pyridoindolone derivatives for preparing medicines |